SOTIO
SOTIO is a biotech company building a diverse portfolio through its own R&D, collaborations, in-licensing, investments, M&A. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is active cellular immunotherapy platform based on dendritic cells. SOTIO is conducting multiple Phase I to III clinical trials verifying the safety and efficacy of its DCVAC products. SOTIO is also developing novel antibody-drug conjugate products, IL15-based immunotherapies and program addressing a novel target in tumor metabolism.